Premium
Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers
Author(s) -
Zhou Honghui,
Choi Les,
Lau Henry,
Bruntsch Ute,
Vries Elisabeth E.G.E.,
Eckhardt Gail,
Oosterom A. T.,
Verweij Jaap,
Schran Horst,
Barbet Nicholas,
Linnartz Ronald,
Capdeville Renaud
Publication year - 2000
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/00912700022008946
Subject(s) - pharmacokinetics , nonmem , medicine , neutropenia , tolerability , population , toxicity , pharmacology , gastroenterology , urology , adverse effect , environmental health
SAM486A (previously termed CGP 48664), a potent inhibitor of S‐adenosylmethionine decarboxylase, is under clinical development for the treatment of advanced refractory malignancies. Hematological toxicity manifested by dose‐dependent neutropenia has been observed in phase I studies. Population methods were used to investigate pharmacokinetics (PK) as a prognostic factor for safety end point (hematological toxicity) in patients with advanced cancers. SAM486A plasma concentrations and neutrophil counts were collected from three ascending‐dose tolerability and PK studies (study 1: single 5‐day continuous intravenous (IV) infusion with doses ranging from 24–700 mg/m 2 /cycle; study 2:10‐minute to 3‐hour IV infusion once weekly with doses ranging from 16–325 mg/m 2 /week; study 3: 1‐hour IV infusion once daily for 5 days with doses ranging from 3.6–202.8 mg/m 2 /day). The PK of SAM486A were best estimated by a population linear three‐compartment model with NONMEM (version 5) using data from 79 patients in studies 1 through 3. The population pharmacokinetic parameters (SD) were CL = 6.2 (0.4) l/h/m 2 , Q 2 = 15.4(1.5) l/h/m 2 , Q 3 , = 33.6 (5.3) l/h/m 2 , V 1 = 9.5 (1.6) l/m 2 , V 2 = 672 (52) l/m 2 , and V 3 = 39.9 (8.3) l/m 2 , and the corresponding intersubject variability was 45.4%, 74.0%, 85.3%, 80.1%, 37.0%, and 103%, respectively, where CL is total body clearance, Q 2 and Q 3 are intercompartmental clearances, and V 1 , V 2 , and V 3 are the volumes of distribution in central and peripheral compartments, respectively. The intrasubject variability was 24.0%. The cumulative AUC before the onset of neutrophil nadir count (AUC) and the duration of exposure over threshold SAM486A concentrations in the range of 0.05 to 0.1 μM based on Bayesian PK parameter estimates significantly correlated with absolute neutrophil count nadir (< 5 × 10 9 /l). AUC showed the best correlation (R 2 = 0.72) with absolute neutrophil count nadir by an inhibitory sigmoid E max model and also correlated with percent decrease in neutrophil count from baseline to nadir by a simple E max model (R 2 = 0.53). Logistic regression analysis indicated that AUC and the duration of exposure over 0.05 to 0.1 μM, but not C max , were strong predictors of grade 4 neutropenia (< 0.5 × 10 9 /l). Drug exposure parameters such as AUC derived from population analysis may be used clinically as a useful predictor of drug‐induced neutropenia.